OncologyCE
EXPERT VIDEOCME

Updates in Genomic Testing for Breast Cancer: Rapid Response From Chicago

Author(s)/Faculty: Ruth O'Regan, MD; William J. Gradishar, MD, FASCO, FACP; Kevin Kalinsky, MD, MS
Release Date: 6/11/2019Expiration Date: 6/10/2020
Credit Type: CMENumber of Credits: 1
Content Type: VideoProvider:
Multigene assays that evaluate an array of prognostic and/or predictive molecular markers have become critical for the optimal management of patients with breast cancer. Although many of these assays can be utilized for prognostication, only some can be used to predict response to therapy, which can be helpful in evaluating patients who have been receiving treatment for several years. For patients with HR+ early-stage breast cancer, assays that can predict response to endocrine therapy may be useful. As the prognostic and/or predictive value of these assays continue to be evaluated for patients with HR+ breast cancer, it is essential that health care professionals have access to these findings. Within this CME activity, experts in the field will differentiate multigene assays for patients with HR+/HER2- breast cancer based on both prognostic and predictive value. They also will review the latest clinical evidence regarding these assays, which can be used to predict response to extended endocrine therapy for patients with HR+/HER2- breast cancer.